American scientists have used LIBRA-seq technology to speed up the search for antibodies that can
“This is one way to proactively createa repertoire of potential therapies against future outbreaks, "explains Ivelin Georgiev, Ph.D., director of the Vanderbilt program in computational microbiology and immunology." Pathogens continue to evolve and we are mostly playing catch-up. "
In my report to the magazine Cell Reports scientists describe how monoclonalantibodies in a patient who has recovered from COVID-19. They are reported to be "showing powerful neutralization" against SARS-CoV-2. The antibodies are also effective against new variants of the coronavirus that are slowing the fight against the pandemic, biologists said.
New antibodies are unusualgenetic and structural characteristics that distinguish it from other monoclonal antibodies commonly used to treat COVID-19. It is believed that SARS-CoV-2 is less likely to mutate to avoid an antibody it has not "seen" before.
LIBRA-seq means B cell bindingreceptor with antigen specificity by sequencing. The method was developed in 2019 by Ian Setliff, Ph.D., a former graduate student at Georgiev's lab who now works in the biotech industry, and Andrea Shiacolas, a current Vanderbilt graduate student.
An airplane with articulated wings and a tail appeared. It can take off without a run
Тепловой парадокс наноматериалов решен. Охладить технику можно в 3 раза эффективнее
An ordinary plane will be turned into a flying laboratory "Excalibur" for fighters
Monoclonal antibodies - antibodies,produced by immune cells belonging to the same cell clone, that is, derived from one plasma progenitor cell (as opposed to polyclonal antibodies).